The Blood Microenvironment Influences the Molecular Phenotypes of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma

2021 ◽  
Vol 41 (2) ◽  
pp. 885-893
Author(s):  
HIROE TADA ◽  
HIDEYUKI TAKAHASHI ◽  
SHOTA IDA ◽  
IKKO MITO ◽  
TOSHIYUKI MATSUYAMA ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
Molecular Phenotypes

scholarly journals Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Hiroe Tada ◽  
Hideyuki Takahashi ◽  
Reika Kawabata-Iwakawa ◽  
Yurino Nagata ◽  
Miho Uchida ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Squamous Cell ◽  
Quantitative Polymerase Chain Reaction ◽  
Neck Squamous Cell Carcinoma ◽  
Expression Level ◽  
Molecular Phenotypes

AbstractThe emergence of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Biomarkers of the therapeutic efficacy of ICIs have been extensively investigated. In this study, we aimed to analyze whether molecular phenotypes of circulating tumor cells (CTCs) are associated with treatment responses and clinical outcomes in patients with R/M HNSCC treated with nivolumab. Peripheral blood samples were collected before treatment initiation and after four infusions of nivolumab. CTCs isolated by depletion of CD45-positive cells were analyzed to determine the expression of EPCAM, MET, KRT19, and EGFR using real-time quantitative polymerase chain reaction. CTC-positive samples were analyzed to determine the expression of PIK3CA, CCND1, SNAI1, VIM, ZEB2, CD44, NANOG, ALDH1A1, CD47, CD274, and PDCD1LG2. Of 30 patients treated with nivolumab, 28 (93.3%) were positive for CTCs. In 20 CTC-positive patients, molecular alterations in CTCs before and after nivolumab treatment were investigated. Patients with MET-positive CTCs had significantly shorter overall survival than those with MET-negative CTCs (p = 0.027). The expression level of CCND1 in CTCs of disease-controlled patients was significantly higher than that of disease-progressed patients (p = 0.034). In disease-controlled patients, the expression level of CCND1 in CTCs significantly decreased after nivolumab treatment (p = 0.043). The NANOG expression in CTCs was significantly increased in disease-controlled patients after nivolumab treatment (p = 0.036). Our findings suggest that the molecular profiling of CTCs is a promising tool to predict the treatment efficacy of nivolumab.

Circulating tumor cells as biomarkers of head and neck squamous cell carcinoma: an updated view

2015 ◽  
Vol 11 (13) ◽  
pp. 1851-1853 ◽  
Author(s):  
Alberto Mangano ◽  
Alessandro Mangano ◽  
Georgios D Lianos ◽  
Luca Levrini ◽  
Monica Picone ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document